Anixa Biosciences Past Earnings Performance
Past criteria checks 0/6
Anixa Biosciences has been growing earnings at an average annual rate of 4%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 32.1% per year.
Key information
4.0%
Earnings growth rate
17.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -32.1% |
| Return on equity | -46.0% |
| Net Margin | -5,116.2% |
| Last Earnings Update | 31 Jan 2024 |
Recent past performance updates
No updates
Recent updates
We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn
Jan 19
We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth
Oct 06Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?
Apr 27Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?
Jan 13We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Sep 26Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial
Aug 15Anixa to get additional US patent linked to breast cancer vaccine technology
Jul 21Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jun 13Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times
May 11We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Feb 24Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth
Oct 28Our First Look At Anixa Biosciences
Sep 23Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation
Jun 12OntoChem assigns Anixa covid-19 drug discovery project to MolGenie
May 07Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jan 13
Anixa Biosciences, Cleveland Clinic in ovarian cancer vaccine pact
Dec 01Revenue & Expenses BreakdownBeta
How Anixa Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jan 24 | 0 | -11 | 7 | 5 |
| 31 Oct 23 | 0 | -10 | 6 | 5 |
| 31 Jul 23 | 0 | -11 | 7 | 5 |
| 30 Apr 23 | 0 | -11 | 6 | 5 |
| 31 Jan 23 | 0 | -12 | 7 | 6 |
| 31 Oct 22 | 0 | -14 | 7 | 7 |
| 31 Jul 22 | 0 | -14 | 7 | 7 |
| 30 Apr 22 | 0 | -16 | 8 | 8 |
| 31 Jan 22 | 0 | -15 | 8 | 7 |
| 31 Oct 21 | 1 | -13 | 7 | 6 |
| 31 Jul 21 | 1 | -11 | 7 | 4 |
| 30 Apr 21 | 1 | -9 | 6 | 4 |
| 31 Jan 21 | 1 | -10 | 6 | 4 |
| 31 Oct 20 | 0 | -10 | 6 | 4 |
| 31 Jul 20 | 0 | -10 | 5 | 5 |
| 30 Apr 20 | 0 | -9 | 5 | 5 |
| 31 Jan 20 | 0 | -9 | 5 | 5 |
| 31 Oct 19 | 0 | -12 | 6 | 5 |
| 31 Jul 19 | 0 | -15 | 7 | 7 |
| 30 Apr 19 | 1 | -18 | 8 | 9 |
| 31 Jan 19 | 1 | -17 | 8 | 8 |
| 31 Oct 18 | 1 | -14 | 7 | 7 |
| 31 Jul 18 | 1 | -10 | 6 | 5 |
| 30 Apr 18 | 1 | -7 | 5 | 2 |
| 31 Jan 18 | 0 | -5 | 5 | 2 |
| 31 Oct 17 | 0 | -7 | 4 | 2 |
| 31 Jul 17 | 1 | -6 | 4 | 2 |
| 30 Apr 17 | 0 | -6 | 3 | 2 |
| 31 Jan 17 | 0 | -7 | 3 | 2 |
| 31 Oct 16 | 0 | -5 | 3 | 2 |
| 31 Jul 16 | 0 | -5 | 3 | 2 |
| 30 Apr 16 | 0 | -6 | 3 | 2 |
| 31 Jan 16 | 0 | -7 | 5 | 1 |
| 31 Oct 15 | 0 | -1 | 6 | 1 |
| 31 Jul 15 | 2 | -3 | 7 | 0 |
| 30 Apr 15 | 3 | -1 | 6 | 0 |
| 31 Jan 15 | 4 | -2 | 6 | 0 |
| 31 Oct 14 | 4 | -10 | 6 | 0 |
| 31 Jul 14 | 3 | -9 | 7 | 0 |
| 30 Apr 14 | 1 | -12 | 8 | 0 |
| 31 Jan 14 | 0 | -12 | 8 | 0 |
| 31 Oct 13 | 0 | -10 | 8 | 0 |
| 31 Jul 13 | 0 | -9 | 7 | 0 |
| 30 Apr 13 | 0 | -7 | 5 | 1 |
Quality Earnings: ANIX is currently unprofitable.
Growing Profit Margin: ANIX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ANIX is unprofitable, but has reduced losses over the past 5 years at a rate of 4% per year.
Accelerating Growth: Unable to compare ANIX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ANIX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: ANIX has a negative Return on Equity (-46.03%), as it is currently unprofitable.